# A Study to Determine Dose, Safety, Tolerability and Efficacy of CC-220 Monotherapy, and in Combination With Other Treatments in Subjects With Multiple

Source: https://onco.cc/trials/nct02773030/  
OnCo record `nct02773030` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Iberdomide, Dexamethasone, Daratumumab in multiple myeloma, run by Celgene, active and no longer recruiting.

## Summary

A Study to Determine Dose, Safety, Tolerability and Efficacy of CC-220 Monotherapy, and in Combination With Other Treatments in Subjects With Multiple Myeloma is a phase 1/2 interventional study registered as NCT02773030 by Celgene, with 466 participants enrolled, started 2016-10-14 and due to reach its primary completion in 2024-05-09. Interventions recorded: CC-220, Dexamethasone, Daratumumab, Bortezomib, Carfilzomib. Conditions listed: Multiple Myeloma. Results were posted on ClinicalTrials.gov in 2026; the figures recorded here are the registry's, not a publication's.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-22
- Tags: ctgov-ingest
- Registry id: NCT02773030
- Phase: 1/2
- Setting: Phase 1b/2a Multicenter, Open-label, Dose-escalation Study to Determine the Maximum Tolerated Dose, Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of CC-220 As Monotherapy and in Combination With Other Treatments in Subjects With Multiple Myeloma
- Sponsor: Celgene
- Enrolled: 466
- Outcomes: Overall Response Rate (ORR) in Cohort D and Cohort H2: Cohort D: Treatment 1 26.2% vs Cohort H2 20%; Progression Free Survival: Cohort A: Total 12.29 weeks vs Cohort B: Total 14.71 weeks vs Cohort D: Total 12.14 weeks vs Cohort E: Total 20.71 weeks vs Cohort F: Total 15.14 weeks vs Cohort G: Total 48.57 weeks vs Cohort H1 26.14 weeks vs Cohort H2 22.14 weeks vs Cohort I 10.14 weeks vs Cohort J: Total 107 weeks vs Cohort K 57.14 weeks

## Sources

- ClinicalTrials.gov NCT02773030: https://clinicaltrials.gov/study/NCT02773030

## Connected records

- cancers: [Multiple myeloma](https://onco.cc/cancers/multiple-myeloma/)
- technologies: [Cereblon E3 ligase modulators (CELMoDs)](https://onco.cc/technologies/celmods/), [PROTACs & molecular glues (targeted protein degradation)](https://onco.cc/technologies/protac-degrader/)
- drugs: [Bortezomib](https://onco.cc/drugs/bortezomib/), [Carfilzomib](https://onco.cc/drugs/carfilzomib/), [Daratumumab](https://onco.cc/drugs/daratumumab/), [Dexamethasone](https://onco.cc/drugs/dexamethasone/), [Iberdomide](https://onco.cc/drugs/iberdomide/)
- companies: [Bristol Myers Squibb](https://onco.cc/companies/bms/)

---
JSON: https://onco.cc/api/v1/entities/nct02773030.json